secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2021-09-14T23:59:59+00:00
Accession:  0001654954-21-010080
Event type: regulatory
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics loses audit committee independence after director resignation; Nasdaq grants cure period
--------------------------------------------------------------------------------

- Director James Mitchum resigned from the Board and its Audit and Compensation Committees effective Sept 8, 2021, for personal reasons.
- Resignation leaves the Audit Committee below the three independent members required by Nasdaq Listing Rule 5605(c)(2)(A).
- Nasdaq granted a cure period ending at the next annual meeting or March 7, 2022, whichever is earlier.
- Company has begun searching for a new independent director to serve on the Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495421010080/0001654954-21-010080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495421010080/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-21-010080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer